Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
hautnah
Erschienen in:

01.05.2015 | Atopische Dermatitis

Genetik der atopischen Dermatitis

verfasst von: Dr. Christine Prodinger, Univ.-Prof. Dr. Johann Bauer, Prof. Priv.-Doz. Dr. Martin Laimer

Erschienen in: hautnah | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die atopische Dermatitis (AD) ist eine häufige multifaktorielle Hauterkrankung mit starkem genetischem Hintergrund. Störungen in der epidermalen Barriere nehmen pathophysiologisch eine zentrale Stellung ein und sind teils zurückzuführen auf Null-Mutationen im Filaggrin-kodierenden Gen (FLG), einem essenziellen Strukturprotein des Stratum corneum. Eine gestörte Barrierefunktion ist eng verknüpft mit chronischer Immunaktivierung in der Haut im Zuge einer systemischen allergischen Reaktion. Es bestehen aber auch Abnormalitäten in den Immunantworten selbst. So konnten in den letzten Jahren, vor allem mittels genomweiter Studien, multiple, mit AD assoziierte Gene identifiziert werden, die unter anderem an Aufbau und Funktion der Hautbarriere, an der epidermalen Proliferation sowie Differenzierung, am Lipidmetabolismus und an der Immunantwort beteiligt sind. In diesem Artikel diskutieren wir die rezenten Erkenntnisse aus dem Bereich der Genetik der atopischen Dermatitis, ihre pathophysiologischen Konsequenzen und mögliche therapeutische Anwendungen.
Vorheriger Artikel Hautbarriere und transepidermale Resorption von Medikamenten
Literatur
1.
2.
Maintz L, Novak N et al (2007) Getting more and more complex: the pathophysiology of atopic eczema. Eur J Dermatol 17:267–283PubMed
3.
McAleer MA, Irvine AD (2013) The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol 131:280–291CrossRefPubMed
4.
5.
Larsen FS, Holm NV, Henningsen K et al (1986) Atopic dermatitis. A genetic-epidemiologic study in a population-based twin sample. J Am Acad Dermatol 15:487–494CrossRefPubMed
6.
Strachan DP, Wong HJ, Spector TD (2001) Concordance and interrelationship of atopic diseases and markers of allergic sensitization among adult female twins. J Allergy Clin Immunol 108:901–907CrossRefPubMed
7.
van Beijsterveldt CE, Boomsma DI (2007) Genetics of parentally reported asthma, eczema and rhinitis in 5-yr-old twins. Eur Respir J 29:516–521CrossRefPubMed
8.
Haagerup A, Bjerke T, Schiotz PO, Dahl R, Binderup HG, Tan Q, Kruse TA (2004) Atopic dermatitis – a total genome-scan for susceptibility genes. Acta Derm Venereol 84:346–352CrossRefPubMed
9.
Bussmann C, Weidinger S, Novak N (2011) Genetischer Hintergrund der atopischen Dermatitis. JDDG 9:670–677PubMed
10.
Cole C, Kroboth K (2014) Filaggrin-stratified transcriptomic analysis of pediatric skin identifies mechanistic pathways in patients with atopic dermatitis. J Allergy Clin Immunol 134(1):82–91CrossRefPubMedCentralPubMed
11.
Weidinger S, Willis-Owen S, Kamatani Y (2013) A genome-wide association study of atopic dermatitis identifies loci with overlapping effects on asthma and psoriasis. Hum Mol Genet 22:4841–4856
12.
Sun LD, Xiao FL, Li Y et al (2011) Genome-wide association study identifies two new susceptibility loci for atopic dermatitis in the Chinese Han population. Nat. Genet 43:690–694CrossRefPubMed
13.
Guttman-Yassky E, Suarez-Farinas M et al (2009) Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. J Allergy Clin Immunol 124:1235–1244.e58CrossRefPubMed
14.
Saaf AM, Tengvall-Linder M, Chang HY et al (2008) Global expression profiling in atopic eczema reveals reciprocal expression of inflammatory and lipid genes. PLoS One 3:e4017CrossRefPubMedCentralPubMed
15.
16.
Hae-Jun L, Seung-Hun L et al (2014) Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis. Allergy Asthma Immunol Res 6(4):276–287CrossRef
17.
Elias PM, Hatano Y, Williams ML (2008) Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol 121:1337–1343CrossRefPubMedCentralPubMed
18.
Palmer CN, Irvine AD et al (2006) Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 38:441–446CrossRefPubMed
19.
Thyssen JP, Godoy-Gijon E, Elias PM (2013) Ichthyosis vulgaris: the filaggrin mutation disease. Br J Dermatol 168:1155–1166CrossRefPubMed
20.
Irvine AD, McLean WH, Leung DY (2011) Filaggrin mutations associated with skin and allergic diseases. N Engl J Med 365:1315–1327CrossRefPubMed
21.
Smith FJ, Irvine AD, Terron-Kwiatkowski A et al (2006) Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet 38:337–342CrossRefPubMed
22.
Brown SJ, Kroboth K, Sandilands A et al (2012) Intragenic copy number variation within filaggrin contributes to the risk of atopic dermatitis with a dose-dependent effect. J Invest Dermatol 132:98–104CrossRefPubMedCentralPubMed
23.
Weidinger S, Rodriguez E, Stahl C et al (2007) Filaggrin mutations strongly predispose to early-onset and extrinsic atopic dermatitis. J Invest Dermatol 127:724–726CrossRefPubMed
24.
Rippke F, Schreiner V, Doering T, Maibach HI (2004) Stratum corneum pH in atopic dermatitis: impact on skin barrier function and colonization with Staphylococcus Aureus. Am J Clin Dermatol 5:217–223CrossRefPubMed
25.
Levin J, Friedlander SF, Del Rosso JQ (2013) Atopic dermatitis and the stratum corneum: part 1: the role of filaggrin in the stratum corneum barrier and atopic skin. J Clin Aesthet Dermatol 6:16–22PubMedCentralPubMed
26.
O’Regan GM, Irvine AD (2010) The role of filaggrin in the atopic diathesis. Clin Exp Allergy 40:965–972CrossRefPubMed
27.
Gao PS, Rafaels NM, H and T, Murray T et al (2009) Filaggrin mutations that confer risk of atopic dermatitis confer greater risk for eczema herpeticum. J Allergy Clin Immunol 124:507–513CrossRefPubMed
28.
Otsuka A, Doi H, Egawa G (2014) Possible new therapeutic strategy to regulate atopic dermatitis through upregulating flaggrin expression. J Allergy Clin Immunol 133(1):139–46.e1–10. doi:10.1016/j.jaci.2013.07.027. Epub 2013 Sep 20CrossRefPubMed
29.
Stout TE, McFarland T, Mitchell JC (2014) Recombinant filaggrin ist internalized and processed to correct filaggrin deficiency. J Invest Dermatol 134(2):423–429. doi:10.1038/jid.2013.284. Epub 2013 Jun 21CrossRefPubMed
30.
Thyssen JP, Kezic S (2014) Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol 134:792–799CrossRefPubMed
31.
Grether-Beck S, Felsner I, Brenden H et al (2012) Urea uptake enhances barrier function and antimicrobial defense in humans by regulating epidermal gene expression. J Invest Dermatol 132:1561–1572CrossRefPubMedCentralPubMed
32.
Hatano Y, Man MQ, Uchida Y et al (2009) Maintenance of an acidic stratum corneum prevents emergence of murine atopic dermatitis. J Invest Dermatol 129:1824–1835CrossRefPubMedCentralPubMed
33.
Elias PM with the editorial assistance of Joan Wakefield (2014) Lipid abnormalities and lipid-based repair strategies in atopic dermatitis. Biochim Biophys Acta 1841:323–330CrossRefPubMedCentralPubMed
34.
Saunders SP, Goh CS, Brown SJ et al (2013) Tmem79/Matt is the matted mouse gene and is a predisposing gene for atopic dermatitis in human subjects. J Allergy Clin Immunol 132:1121–1129CrossRefPubMedCentralPubMed
35.
Sasaki T, Shiohama A, Kubo A et al (2013) A homozygous nonsense mutation in the gene for Tmem79, a component for the lamellar granule secretory system, produces spontaneous eczema in an experimental model of atopic dermatitis. J Allergy Clin Immunol 132:1111–1120.e4CrossRefPubMed
36.
Kircik LH, Del Rosso JQ (2011) Nonsteroidal treatment of atopic dermatitis in pediatric patients with a ceramide-dominant topical emulsion formulated with an optimized ratio of physiological lipids. J Clin Aesthet Dermatol 4:25–31PubMedCentralPubMed
37.
De Benedetto A, Rafaels NM, McGirt LY et al (2011) Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol 127:773–786.e1–7CrossRefPubMedCentralPubMed
38.
Baek JH, Lee SE, Choi KJ, Choi EH, Lee SH (2013) Acute modulations in stratum corneum permeability barrier function affect claudin expression and epidermal tight junction function via changes of epidermal calcium gradient. Yonsei Med J 54:523–528CrossRefPubMedCentralPubMed
39.
Sugawara T, Iwamoto N, Akashi M et al (2013) Tight junction dysfunction in the stratum granulosum leads to aberrant stratum corneum barrier function in claudin-1-deficient mice. J Dermatol Sci 70:12–18CrossRefPubMed
40.
Kuo IH, Carpenter-Mendini A, Yoshida T et al (2013) Activation of epidermal toll-like receptor 2 enhances tight junction function: implications for atopic dermatitis and skin barrier repair. J Invest Dermatol 133:988–998CrossRefPubMedCentralPubMed
41.
Levin J, Friedlander SF, Del Rosso JQ (2013) Atopic dermatitis and the stratum corneum: part 3: the immune system in atopic dermatitis. J Clin Aesthet Dermatol 6(12):37–44PubMedCentralPubMed
42.
Hirasawa Y, Takai T, Nakamura T et al (2010) Staphylococcus aureus extracellular protease causes epidermal barrier dysfunction. J Invest Dermatol 130:614–617CrossRefPubMed
43.
Brattsand M, Stefansson K, Lundh C, Haasum Y, Egelrud T (2005) A proteolytic cascade of kallikreins in the stratum corneum. J Invest Dermatol 124:198–203CrossRefPubMed
44.
Furio L, Hovnanian A (2014) Netherton syndrome: defective kallikrein inhibition in the skin leads to skin inflammation and allergy. Biol Chem 395(9):945–958CrossRefPubMed
45.
Hachem JP, Houben E, Crumrine D et al (2006) Serine protease signaling of epidermal permeability barrier homeostasis. J Invest Dermatol 126:2074–2086CrossRefPubMed
46.
Lee SE, Jeong SK, Lee SH (2010) Protease and protease-activated receptor-2 signaling in the pathogenesis of atopic dermatitis. Yonsei Med J 51:808–822CrossRefPubMedCentralPubMed
47.
Zhao LP, Di Z, Zhang L et al (2012) Association of SPINK5 gene polymorphisms with atopic dermatitis in Northeast China. J Eur Acad Dermatol Venereol 26:572–577CrossRefPubMed
48.
Lee HJ, Yoon NY (2014) Topical acidic cream prevents the development of atopic dermatitis – and asthma-lika lesions in murine model. Exp Dermatol 23:736–741CrossRefPubMed
49.
Hatano Y, Elias PM, Crumrine D et al (2011) Efficacy of combined peroxisome proliferator-activated receptor-alpha ligand and glucocorticoid therapy in a murine model of atopic dermatitis. J Invest Dermatol 131:1845–1852CrossRefPubMedCentralPubMed
50.
Kim B, Choi YE, Kim HS (2014) Eruca sativa and ist flavonoid components, quercetin and isorhamnetin, improve skin barrier funkction by activation of peroxisome proliferator-activated receptor (PPAR)-alpha and suppression of inflammatory cytokines. Phytother Res 28:1359–1366CrossRefPubMed
51.
van den Bogaard EH, Bergboer JG, Vonk-Bergers M et al (2013) Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. J Clin Invest 123:917–927PubMedCentralPubMed
52.
Park K, Lee S, Lee YM (2013) Sphingolipids and antimicrobial peptides: function and roles in atopic dermatitis. Biomol Ther (Seoul) 21(4):251–257CrossRef
53.
Guttman-Yassky E, Nograles KE, Krueger JG (2011) Contrasting pathogenesis of atopic dermatitis and psoriasis–Part II: immune cell subsets and therapeutic concepts. J Allergy Clin Immunol 127:1420–1432CrossRefPubMed
54.
Oh DY, Schumann RR, Hamann L, Neumann K, Worm M, Heine G (2009) Association of the toll-like receptor 2 A-16934T promoter polymorphism with severe atopic dermatitis. Allergy 64:1608–1615CrossRefPubMed
55.
Niebuhr M, Langnickel J, Sigel S, Werfel T (2010) Dysregulation of CD36 upon TLR-2 stimulation in monocytes from patients with atopic dermatitis and the TLR2 R753Q polymorphism. Exp Dermatol 19:e296–e298CrossRefPubMed
56.
Rothenbacher D, Weyermann M, Beermann C et al(2005) Breastfeeding, soluble CD 14 concentration in breast milk and risk of atopic dermatitis and asthma in early childhood: birth cohort study. Clin Exp Allergy 35(8):1014–1021CrossRefPubMed
57.
58.
Kondo H, Ichikawa Y, Imokawa G (1998) Percutaneous sensitization with allergens through barrier-disrupted skin elicits a Th2-dominant cytokine response. Eur J Immunol 28(3):769–779CrossRefPubMed
59.
Kaminishi K (2002) Flow cytometric analysis of IL-4, IL-13 and IFN-γ expression in peripheral blood mononuclear cells and detection of circulating IL-13 in patients with atopic dermatitis provide evidence for the involvement of type 2 cytokines in the disease. J Dermatol Sci 29:19–25CrossRefPubMed
60.
Afshar M, Gallo RL (2013) Innate immune defense system of the skin. Vet Dermatol 24:32–38.e8–9CrossRefPubMed
61.
Yagi R, Nagai H, Iigo Y, Akimoto T, Arai T, Kubo M (2002) Development of atopic dermatitis-like skin lesions in STAT6-deficient NC/Nga mice. J Immunol 168:2020–2027CrossRefPubMed
62.
Nedoszytko B, Sokolowska-Wojdylo M (2014) Chemokines and cytokines network in the pathogenesis oft he inflammatory skin diseases: atopic dermatitis, psoriases and skin mastocytosis. Postepy Dermatol Alergol 31(2):84–91CrossRefPubMedCentralPubMed
63.
Sokołowska-Wojdyło M, Gleń J, Zabłotna M et al (2012) Association of distinct IL-31 polymorphisms with pruritus and severity of atopic dermatitis. J Eur Acad Dermatol Venereol 27:662-664CrossRefPubMed
64.
65.
He JQ, Chan-Yeung M, Becker AB, mich-Ward H, Ferguson AC, Manfreda J, Watson WT, Sandford AJ (2003) Genetic variants of the IL13 and IL4 genes and atopic diseases in at-risk children. Genes Immun 4:385–389CrossRefPubMed
66.
Weidinger S, Klopp N, Wagenpfeil S, Rummler L et al (2004) Association of a STAT 6 haplotype with elevated serum IgE levels in a population based cohort of white adults. J Med Genet 41:658–663CrossRefPubMedCentralPubMed
67.
68.
Beck LA, Thaci D, Hamilton JD et al (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371(2):130–139CrossRefPubMed
69.
70.
Sano Y, Masuda K, Tamagawa-Mineoka R et al (2013) Thymic stromal lymphopoietin expression is increased in the horny layer of patients with atopic dermatitis. Clin Exp Immuno 171(3):330–337CrossRef
71.
Kubo T, Kemkura R (2014) ΔNp63 controls a tlr3-mediated mechanism that abundantly provides thymic stromal lymphopoietin in atopic dermatitis. PLoS One 9(8):e105498CrossRefPubMedCentralPubMed
Metadaten
Titel
Genetik der atopischen Dermatitis
verfasst von
Dr. Christine Prodinger
Univ.-Prof. Dr. Johann Bauer
Prof. Priv.-Doz. Dr. Martin Laimer
Publikationsdatum
01.05.2015
Verlag
Springer Vienna
Erschienen in
hautnah / Ausgabe 2/2015
Print ISSN: 1866-2250
Elektronische ISSN: 2192-6484
DOI
https://doi.org/10.1007/s12326-014-0138-9

Weitere Artikel der Ausgabe 2/2015

Hautkrebs per SMS verhindern

  • aktuell

Targeted Therapies

  • ÖGDV-Jahrestagung 2014

Wertvoller Begleiter durch die Pollensaison

  • aktuell

Hautbarriere und transepidermale Resorption von Medikamenten

  • ÖGDV-Jahrestagung 2014

Infektionskrankheiten der Haut

  • ÖGDV-Jahrestagung 2014